Veracyte, Inc. reported expected total revenue of $138-$140 million and testing revenue of $134-$136 million for Q4 2025, alongside full-year revenue projections of $515-$517 million with an adjusted EBITDA margin exceeding 25%. These estimates are unaudited and subject to final adjustments.